NASDAQ:AKAO - Nasdaq -
0.11
+0 (+2.23%)
The current stock price of AKAO is 0.11 null. In the past month the price decreased by -76.66%. In the past year, price decreased by -99.16%.
Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California.
Achaogen Inc
1 TOWER PLACE SUITE 300
SOUTH SAN FRANCISCO CA 94080
CEO: Blake Wise
Phone: 650-800-3636
The current stock price of AKAO is 0.11 null. The price increased by 2.23% in the last trading session.
The exchange symbol of Achaogen Inc is AKAO and it is listed on the Nasdaq exchange.
AKAO stock is listed on the Nasdaq exchange.
Achaogen Inc (AKAO) has a market capitalization of 7.03M null. This makes AKAO a Nano Cap stock.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AKAO does not pay a dividend.
Achaogen Inc (AKAO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.7).
ChartMill assigns a fundamental rating of 2 / 10 to AKAO. Both the profitability and financial health of AKAO have multiple concerns.
Over the last trailing twelve months AKAO reported a non-GAAP Earnings per Share(EPS) of -3.7. The EPS decreased by -16.72% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -2136.94% | ||
ROA | -226.65% | ||
ROE | 2966.63% | ||
Debt/Equity | -3.94 |
ChartMill assigns a Buy % Consensus number of 60% to AKAO. The Buy consensus is the average rating of analysts ratings from 5 analysts.